Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. [PDF]
Ueno D +17 more
europepmc +1 more source
Olaparib‐associated cutaneous vasculitis in a patient with breast cancer
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marcial Álvarez‐Salafranca +3 more
wiley +1 more source
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis. [PDF]
Cheng CC +11 more
europepmc +1 more source
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. [PDF]
Taylor AM +6 more
europepmc +1 more source
Cinnamaldehyde derived from Cinnamomum species exerts multitarget anticancer effects by promoting oxidative stress, mitochondrial dysfunction, apoptosis, cell‐cycle arrest, autophagy, and epigenetic changes, and by suppressing mitogen‐activated protein kinase (MAPK), phosphoinositide 3‐kinase/protein kinase B/mechanistic target of rapamycin (PI3K/Akt ...
Gervason Moriasi +6 more
wiley +1 more source
Novel clinical potential of poly (ADP‑ribose) polymerase inhibitors in triple‑negative breast cancer: Mechanistic insights and clinical applications (Review). [PDF]
Han Y, Wei L.
europepmc +1 more source
RAD21 Confers Poor Prognosis and Affects Ovarian Cancer Sensitivity to Poly(ADP-Ribose)Polymerase Inhibitors Through DNA Damage Repair. [PDF]
Gou R +6 more
europepmc +1 more source
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng +9 more
wiley +1 more source
Clinical Outcomes of Poly(ADP-Ribose) Polymerase Inhibitors as Maintenance Therapy in Patients with Ovarian Cancer in the Southeastern Region of Korea. [PDF]
Ha HI +7 more
europepmc +1 more source

